Double antiglutamatergic treatment in patients with status epilepticus: A case series

Published:November 11, 2022DOI:


      • Status epilepticus is a neurological emergency that requires timely administration of appropriate medications.
      • Ketamine effect of noncompetitive NMDA receptor antagonism was augmented by co-administering perampanel acting at AMPA receptors.
      • Data is limited on the use of perampanel in humans.
      • This combination could provide if validated, a novel approach to treating status epilepticus.



      Status epilepticus (SE) continues to be a challenging neurological emergency with high morbidity and mortality. During treatment, different regimens are practiced encompassing all known seizure termination mechanisms. To our knowledge, this is the first case series report describing EEG patterns and clinical outcomes in patients treated with ketamine and perampanel (PER) concomitantly.


      To assess clinical and electrographic outcomes in patients receiving dual antiglutamatergic therapy in SE.


      Twenty-one out of twenty five patients were treated with ketamine, and four patients with ketamine were associated with PER. In the ketamine plus PER group, three out of four patients had convulsive SE, and one had non-convulsive status epilepticus (NCSE), whereas eight patients in the ketamine group had NCSE. The incidence of beta pattern appearance on EEG after starting patients on ketamine and PER was achieved in all four patients (100%) compared to (61.9%) in the other group. A burst suppression pattern was recorded in 75% of patients treated with ketamine and PER, in comparison to 28.5% of patients in patients treated with a different regimen. The time to resolution of SE was significantly shorter in the ketamine group (median 24 (24–64) h vs. 6 (05–144) h p > 0.05). Moreover, the average number of days on IV anesthetic was slightly lower in a patient treated with PER concomitantly. In terms of morbidity, the average increase in mRS was also lower in the ketamine and PER group, although it was not statistically significant.


      Dual anti-glutamatergic therapy could provide a favorable approach to treating SE, which yet needs to be further investigated through larger randomized control studies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Epilepsy & Behavior
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Marik P.E.
        Propofol: therapeutic indications and side-effects.
        Curr Pharm Des. 2004; 10: 3639-3649
        • Smith M.
        Anesthestic agents and status epilepticus.
        Epilepsia. 2011; 52: 42-44
        • Patsalos P.N.
        The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.
        Epilepsia. 2015; 56: 12-27
        • Rogawski M.A.
        • Hanada T.
        Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist.
        Acta Neurol Scand Suppl. 2013; 197: 19-24
        • Trinka E.
        • Cock H.
        • Hesdorffer D.
        • Rossetti A.O.
        • Scheffer I.E.
        • Shinnar S.
        • et al.
        A definition and classification of status epilepticus–Report of the ILAE Task Force on Classification of Status Epilepticus.
        Epilepsia. 2015; 56: 1515-1523
        • Walker M.C.
        Pathophysiology of status epilepticus.
        Neurosci Lett. 2018; 22: 84-91
        • Hanada T.
        • Ido K.
        • Kosasa T.
        Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model.
        Pharmacol Res Perspect. 2014; 2: e00063
        • Rosati A.
        • De Masi S.
        • Guerrini R.
        Ketamine for refractory status epilepticus: a systematic review.
        CNS Drugs. 2018; 32: 997-1009
        • Alkhachroum A.
        • Der-Nigoghossian C.A.
        • Mathews E.
        • Massad N.
        • Letchinger R.
        • Doyle K.
        • et al.
        Ketamine to treat super-refractory status epilepticus.
        Neurology. 2020; 95: e2286-e2294
        • Ilvento L.
        • Rosati A.
        • Marini C.
        • L'Erario M.
        • Mirabile L.
        • Guerrini R.
        Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation.
        Epilepsy Behav. 2015; 49: 343-346
        • Machado R.A.
        • Patel J.
        • Elsayed M.S.
        The role of ketamine-induced beta activity in the treatment of refractory status epilepticus. Is the EEG useful to determine responder's rate? A retrospective study.
        Epilepsy Behav. 2022; 127: 108512
        • Peltoniemi M.A.
        • Hagelberg N.M.
        • Olkkola K.T.
        • Saari T.I.
        Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy.
        Clin Pharmacokinet. 2016; 55: 1059-1077
        • Wang L.
        • Deng B.
        • Yan P.
        • Wu H.
        • Li C.
        • Zhu H.
        • et al.
        Neuroprotective effect of ketamine against TNF-α-induced necroptosis in hippocampal neurons.
        J Cell Mol Med. 2021; 25: 3449-3459